(LDOS) Leidos Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5253271028
Stock: Software, Intelligence, Cybersecurity, Aviation, Healthcare
Total Rating 59
Risk 94
Buy Signal -0.16
| Risk 5d forecast | |
|---|---|
| Volatility | 42.3% |
| Relative Tail Risk | -30.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.14 |
| Alpha | 24.23 |
| Character TTM | |
|---|---|
| Beta | 0.783 |
| Beta Downside | 0.319 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.86% |
| CAGR/Max DD | 0.67 |
EPS (Earnings per Share)
Revenue
Description: LDOS Leidos Holdings March 01, 2026
Leidos Holdings (NYSE: LDOS) delivers integrated technology and engineering services across four primary segments: National Security & Digital, Health & Civil, Commercial & International, and Defense Systems. The company supports U.S. and global government and commercial clients with solutions ranging from AI-driven warfighter tools and cyber-operations to air traffic control, health-mission software, power-grid modernization, and advanced defense sensors.
In fiscal 2023, Leidos reported revenue of $13.5 billion, a 7% year-over-year increase, driven by strong growth in its National Security & Digital and Defense Systems businesses. The firm’s backlog now exceeds $30 billion, reflecting a robust pipeline of multi-year federal contracts, particularly in AI-enabled intelligence analysis and next-generation missile-defense systems.
Key sector drivers include the U.S. defense budget’s projected 3.5% rise in FY2025, heightened demand for cybersecurity and cloud modernization across federal agencies, and accelerating investments in grid resilience and renewable-energy integration-areas where Leidos’ Commercial & International segment is positioned to capture market share.
For deeper insights, you might explore ValueRay’s detailed analysis of LDOS.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.46b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 2.08 > 1.0 |
| NWC/Revenue: 11.57% < 20% (prev 4.65%; Δ 6.92% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.75b > Net Income 1.46b |
| Net Debt (4.72b) to EBITDA (2.41b): 1.96 < 3 |
| Current Ratio: 1.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (132.4m) vs 12m ago -1.19% < -2% |
| Gross Margin: 17.66% > 18% (prev 0.17%; Δ 1749 % > 0.5%) |
| Asset Turnover: 129.1% > 50% (prev 127.2%; Δ 1.99% > 0%) |
| Interest Coverage Ratio: 10.38 > 6 (EBITDA TTM 2.41b / Interest Expense TTM 203.0m) |
Altman Z'' 3.72
| A: 0.15 (Total Current Assets 4.81b - Total Current Liabilities 2.83b) / Total Assets 13.49b |
| B: 0.34 (Retained Earnings 4.65b / Total Assets 13.49b) |
| C: 0.16 (EBIT TTM 2.11b / Avg Total Assets 13.30b) |
| D: 0.54 (Book Value of Equity 4.60b / Total Liabilities 8.53b) |
| Altman-Z'' Score: 3.72 = AA |
Beneish M -3.09
| DSRI: 0.99 (Receivables 2.71b/2.65b, Revenue 17.17b/16.66b) |
| GMI: 0.95 (GM 17.66% / 16.79%) |
| AQI: 0.98 (AQ_t 0.53 / AQ_t-1 0.54) |
| SGI: 1.03 (Revenue 17.17b / 16.66b) |
| TATA: -0.02 (NI 1.46b - CFO 1.75b) / TA 13.49b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of LDOS shares?
As of March 03, 2026, the stock is trading at USD 179.40 with a total of 1,579,080 shares traded.
Over the past week, the price has changed by +4.30%, over one month by -4.59%, over three months by -3.88% and over the past year by +40.27%.
Over the past week, the price has changed by +4.30%, over one month by -4.59%, over three months by -3.88% and over the past year by +40.27%.
Is LDOS a buy, sell or hold?
Leidos Holdings has received a consensus analysts rating of 4.06.
Therefore, it is recommended to buy LDOS.
- StrongBuy: 8
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LDOS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 214 | 19.3% |
| Analysts Target Price | 214 | 19.3% |
LDOS Fundamental Data Overview March 03, 2026
P/E Trailing = 15.7181
P/E Forward = 13.6426
P/S = 1.3036
P/B = 4.5019
P/EG = 2.34
Revenue TTM = 17.17b USD
EBIT TTM = 2.11b USD
EBITDA TTM = 2.41b USD
Long Term Debt = 4.63b USD (from longTermDebt, last quarter)
Short Term Debt = 127.0m USD (from shortTermDebt, last quarter)
Debt = 5.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.72b USD (from netDebt column, last quarter)
Enterprise Value = 27.11b USD (22.39b + Debt 5.93b - CCE 1.20b)
Interest Coverage Ratio = 10.38 (Ebit TTM 2.11b / Interest Expense TTM 203.0m)
EV/FCF = 16.68x (Enterprise Value 27.11b / FCF TTM 1.62b)
FCF Yield = 5.99% (FCF TTM 1.62b / Enterprise Value 27.11b)
FCF Margin = 9.46% (FCF TTM 1.62b / Revenue TTM 17.17b)
Net Margin = 8.48% (Net Income TTM 1.46b / Revenue TTM 17.17b)
Gross Margin = 17.66% ((Revenue TTM 17.17b - Cost of Revenue TTM 14.14b) / Revenue TTM)
Gross Margin QoQ = 16.0% (prev 18.37%)
Tobins Q-Ratio = 2.01 (Enterprise Value 27.11b / Total Assets 13.49b)
Interest Expense / Debt = 0.81% (Interest Expense 48.0m / Debt 5.93b)
Taxrate = 20.84% (88.2m / 423.2m)
NOPAT = 1.67b (EBIT 2.11b * (1 - 20.84%))
Current Ratio = 1.70 (Total Current Assets 4.81b / Total Current Liabilities 2.83b)
Debt / Equity = 1.21 (Debt 5.93b / totalStockholderEquity, last quarter 4.92b)
Debt / EBITDA = 1.96 (Net Debt 4.72b / EBITDA 2.41b)
Debt / FCF = 2.91 (Net Debt 4.72b / FCF TTM 1.62b)
Total Stockholder Equity = 4.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.95% (Net Income 1.46b / Total Assets 13.49b)
RoE = 31.07% (Net Income TTM 1.46b / Total Stockholder Equity 4.69b)
RoCE = 22.61% (EBIT 2.11b / Capital Employed (Equity 4.69b + L.T.Debt 4.63b))
RoIC = 17.42% (NOPAT 1.67b / Invested Capital 9.57b)
WACC = 7.09% (E(22.39b)/V(28.32b) * Re(8.80%) + D(5.93b)/V(28.32b) * Rd(0.81%) * (1-Tc(0.21)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.05%
[DCF] Terminal Value 82.80% ; FCFF base≈1.50b ; Y1≈1.66b ; Y5≈2.17b
[DCF] Fair Price = 323.6 (EV 45.63b - Net Debt 4.72b = Equity 40.90b / Shares 126.4m; r=7.09% [WACC]; 5y FCF grow 12.68% → 2.90% )
EPS Correlation: 91.68 | EPS CAGR: 16.04% | SUE: 0.73 | # QB: 0
Revenue Correlation: 95.93 | Revenue CAGR: 5.08% | SUE: -1.30 | # QB: 0
EPS next Quarter (2026-06-30): EPS=3.03 | Chg7d=-0.008 | Chg30d=-0.016 | Revisions Net=-3 | Analysts=12
EPS current Year (2026-12-31): EPS=12.34 | Chg7d=+0.022 | Chg30d=-0.008 | Revisions Net=-2 | Growth EPS=+2.9% | Growth Revenue=+3.5%
EPS next Year (2027-12-31): EPS=12.92 | Chg7d=+0.139 | Chg30d=+0.055 | Revisions Net=+2 | Growth EPS=+4.7% | Growth Revenue=+4.1%
[Analyst] Revisions Ratio: -0.43 (2 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.4% (Discount Rate 8.8% - Earnings Yield 6.4%)
[Growth] Growth Spread = -0.1% (Analyst 2.4% - Implied 2.4%)
P/E Forward = 13.6426
P/S = 1.3036
P/B = 4.5019
P/EG = 2.34
Revenue TTM = 17.17b USD
EBIT TTM = 2.11b USD
EBITDA TTM = 2.41b USD
Long Term Debt = 4.63b USD (from longTermDebt, last quarter)
Short Term Debt = 127.0m USD (from shortTermDebt, last quarter)
Debt = 5.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.72b USD (from netDebt column, last quarter)
Enterprise Value = 27.11b USD (22.39b + Debt 5.93b - CCE 1.20b)
Interest Coverage Ratio = 10.38 (Ebit TTM 2.11b / Interest Expense TTM 203.0m)
EV/FCF = 16.68x (Enterprise Value 27.11b / FCF TTM 1.62b)
FCF Yield = 5.99% (FCF TTM 1.62b / Enterprise Value 27.11b)
FCF Margin = 9.46% (FCF TTM 1.62b / Revenue TTM 17.17b)
Net Margin = 8.48% (Net Income TTM 1.46b / Revenue TTM 17.17b)
Gross Margin = 17.66% ((Revenue TTM 17.17b - Cost of Revenue TTM 14.14b) / Revenue TTM)
Gross Margin QoQ = 16.0% (prev 18.37%)
Tobins Q-Ratio = 2.01 (Enterprise Value 27.11b / Total Assets 13.49b)
Interest Expense / Debt = 0.81% (Interest Expense 48.0m / Debt 5.93b)
Taxrate = 20.84% (88.2m / 423.2m)
NOPAT = 1.67b (EBIT 2.11b * (1 - 20.84%))
Current Ratio = 1.70 (Total Current Assets 4.81b / Total Current Liabilities 2.83b)
Debt / Equity = 1.21 (Debt 5.93b / totalStockholderEquity, last quarter 4.92b)
Debt / EBITDA = 1.96 (Net Debt 4.72b / EBITDA 2.41b)
Debt / FCF = 2.91 (Net Debt 4.72b / FCF TTM 1.62b)
Total Stockholder Equity = 4.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.95% (Net Income 1.46b / Total Assets 13.49b)
RoE = 31.07% (Net Income TTM 1.46b / Total Stockholder Equity 4.69b)
RoCE = 22.61% (EBIT 2.11b / Capital Employed (Equity 4.69b + L.T.Debt 4.63b))
RoIC = 17.42% (NOPAT 1.67b / Invested Capital 9.57b)
WACC = 7.09% (E(22.39b)/V(28.32b) * Re(8.80%) + D(5.93b)/V(28.32b) * Rd(0.81%) * (1-Tc(0.21)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.05%
[DCF] Terminal Value 82.80% ; FCFF base≈1.50b ; Y1≈1.66b ; Y5≈2.17b
[DCF] Fair Price = 323.6 (EV 45.63b - Net Debt 4.72b = Equity 40.90b / Shares 126.4m; r=7.09% [WACC]; 5y FCF grow 12.68% → 2.90% )
EPS Correlation: 91.68 | EPS CAGR: 16.04% | SUE: 0.73 | # QB: 0
Revenue Correlation: 95.93 | Revenue CAGR: 5.08% | SUE: -1.30 | # QB: 0
EPS next Quarter (2026-06-30): EPS=3.03 | Chg7d=-0.008 | Chg30d=-0.016 | Revisions Net=-3 | Analysts=12
EPS current Year (2026-12-31): EPS=12.34 | Chg7d=+0.022 | Chg30d=-0.008 | Revisions Net=-2 | Growth EPS=+2.9% | Growth Revenue=+3.5%
EPS next Year (2027-12-31): EPS=12.92 | Chg7d=+0.139 | Chg30d=+0.055 | Revisions Net=+2 | Growth EPS=+4.7% | Growth Revenue=+4.1%
[Analyst] Revisions Ratio: -0.43 (2 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.4% (Discount Rate 8.8% - Earnings Yield 6.4%)
[Growth] Growth Spread = -0.1% (Analyst 2.4% - Implied 2.4%)